Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380433612> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4380433612 endingPage "2733" @default.
- W4380433612 startingPage "2723" @default.
- W4380433612 abstract "To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D).This was a phase 1, double-blind, randomized, placebo-controlled, two-part trial with a 12-week treatment period of once-weekly subcutaneous HM15136 (0.02/0.04/0.06 mg/kg). Part 1 included patients with dyslipidaemia and/or hypertension and no T2D. Part 2 included patients with dyslipidaemia and/or hypertension plus T2D.In part 1, 23/27 (85.2%) patients receiving HM15136 and all patients receiving placebo (9/9 [100%]) experienced a treatment-emergent adverse event (TEAE). Five of 27 (18.5%) patients receiving HM15136 developed anti-HM15136 antibodies. Dose-dependent increases in mean HM15136 serum concentration and fasting plasma glucose (FPG) were observed, as were dose-dependent weight reductions of 0.5%/2.3%/2.6% at doses of 0.02/0.04/0.06 mg/kg, respectively. In part 2, 8/12 (66.7%) patients receiving HM15136 and all patients receiving placebo (4/4 [100.0%]) reported a TEAE. Two (16.7%) patients developed anti-HM15136 antibodies. Dose-dependent increases in mean HM15136 serum concentration were observed. FPG of more than 200 mg/dL was reported in 4/9 (44.4%) and 2/3 (66.7%) patients receiving 0.02 and 0.06 mg/kg, respectively. The 0.06 mg/kg dose was not tolerated in part 2 because of hyperglycaemia. Patients receiving 0.02 mg/kg showed a 0.9% weight reduction. No serious TEAEs leading to discontinuation were reported in either study part.This study of HM15136 provides a preliminary safety and tolerability profile with initial insights into its efficacy profile." @default.
- W4380433612 created "2023-06-14" @default.
- W4380433612 creator A5028289286 @default.
- W4380433612 creator A5032715085 @default.
- W4380433612 creator A5043015378 @default.
- W4380433612 creator A5044166679 @default.
- W4380433612 creator A5054210089 @default.
- W4380433612 creator A5054343172 @default.
- W4380433612 date "2023-06-13" @default.
- W4380433612 modified "2023-10-18" @default.
- W4380433612 title "Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue <scp>HM15136</scp> in overweight and obese patients with co‐morbidities" @default.
- W4380433612 cites W1798757189 @default.
- W4380433612 cites W2154406386 @default.
- W4380433612 cites W2301441485 @default.
- W4380433612 cites W2591832038 @default.
- W4380433612 cites W2592545469 @default.
- W4380433612 cites W2737611067 @default.
- W4380433612 cites W2948135344 @default.
- W4380433612 cites W2967453995 @default.
- W4380433612 cites W3108412012 @default.
- W4380433612 cites W3121704649 @default.
- W4380433612 cites W3123792142 @default.
- W4380433612 cites W3174358669 @default.
- W4380433612 cites W3196530901 @default.
- W4380433612 cites W3210607323 @default.
- W4380433612 cites W4200454061 @default.
- W4380433612 cites W4229044486 @default.
- W4380433612 cites W4281934192 @default.
- W4380433612 cites W4285035640 @default.
- W4380433612 cites W4302774178 @default.
- W4380433612 doi "https://doi.org/10.1111/dom.15162" @default.
- W4380433612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37311732" @default.
- W4380433612 hasPublicationYear "2023" @default.
- W4380433612 type Work @default.
- W4380433612 citedByCount "0" @default.
- W4380433612 crossrefType "journal-article" @default.
- W4380433612 hasAuthorship W4380433612A5028289286 @default.
- W4380433612 hasAuthorship W4380433612A5032715085 @default.
- W4380433612 hasAuthorship W4380433612A5043015378 @default.
- W4380433612 hasAuthorship W4380433612A5044166679 @default.
- W4380433612 hasAuthorship W4380433612A5054210089 @default.
- W4380433612 hasAuthorship W4380433612A5054343172 @default.
- W4380433612 hasBestOaLocation W43804336121 @default.
- W4380433612 hasConcept C111113717 @default.
- W4380433612 hasConcept C112705442 @default.
- W4380433612 hasConcept C126322002 @default.
- W4380433612 hasConcept C134018914 @default.
- W4380433612 hasConcept C142724271 @default.
- W4380433612 hasConcept C197934379 @default.
- W4380433612 hasConcept C204787440 @default.
- W4380433612 hasConcept C27081682 @default.
- W4380433612 hasConcept C2777180221 @default.
- W4380433612 hasConcept C2778375690 @default.
- W4380433612 hasConcept C2780586474 @default.
- W4380433612 hasConcept C511355011 @default.
- W4380433612 hasConcept C555293320 @default.
- W4380433612 hasConcept C71924100 @default.
- W4380433612 hasConcept C90924648 @default.
- W4380433612 hasConcept C98274493 @default.
- W4380433612 hasConceptScore W4380433612C111113717 @default.
- W4380433612 hasConceptScore W4380433612C112705442 @default.
- W4380433612 hasConceptScore W4380433612C126322002 @default.
- W4380433612 hasConceptScore W4380433612C134018914 @default.
- W4380433612 hasConceptScore W4380433612C142724271 @default.
- W4380433612 hasConceptScore W4380433612C197934379 @default.
- W4380433612 hasConceptScore W4380433612C204787440 @default.
- W4380433612 hasConceptScore W4380433612C27081682 @default.
- W4380433612 hasConceptScore W4380433612C2777180221 @default.
- W4380433612 hasConceptScore W4380433612C2778375690 @default.
- W4380433612 hasConceptScore W4380433612C2780586474 @default.
- W4380433612 hasConceptScore W4380433612C511355011 @default.
- W4380433612 hasConceptScore W4380433612C555293320 @default.
- W4380433612 hasConceptScore W4380433612C71924100 @default.
- W4380433612 hasConceptScore W4380433612C90924648 @default.
- W4380433612 hasConceptScore W4380433612C98274493 @default.
- W4380433612 hasIssue "9" @default.
- W4380433612 hasLocation W43804336121 @default.
- W4380433612 hasLocation W43804336122 @default.
- W4380433612 hasOpenAccess W4380433612 @default.
- W4380433612 hasPrimaryLocation W43804336121 @default.
- W4380433612 hasRelatedWork W1830687917 @default.
- W4380433612 hasRelatedWork W1934667138 @default.
- W4380433612 hasRelatedWork W1966047811 @default.
- W4380433612 hasRelatedWork W2003042623 @default.
- W4380433612 hasRelatedWork W202460821 @default.
- W4380433612 hasRelatedWork W2074207917 @default.
- W4380433612 hasRelatedWork W2090169689 @default.
- W4380433612 hasRelatedWork W2329478898 @default.
- W4380433612 hasRelatedWork W2538072326 @default.
- W4380433612 hasRelatedWork W4298086959 @default.
- W4380433612 hasVolume "25" @default.
- W4380433612 isParatext "false" @default.
- W4380433612 isRetracted "false" @default.
- W4380433612 workType "article" @default.